MX2015000076A - Uso de 2-metileno-19-nor- (20s) -1a, 25-dihidroxivitamina d3 para tratar el hiperparatiroidismo secundario. - Google Patents

Uso de 2-metileno-19-nor- (20s) -1a, 25-dihidroxivitamina d3 para tratar el hiperparatiroidismo secundario.

Info

Publication number
MX2015000076A
MX2015000076A MX2015000076A MX2015000076A MX2015000076A MX 2015000076 A MX2015000076 A MX 2015000076A MX 2015000076 A MX2015000076 A MX 2015000076A MX 2015000076 A MX2015000076 A MX 2015000076A MX 2015000076 A MX2015000076 A MX 2015000076A
Authority
MX
Mexico
Prior art keywords
secondary hyperparathyroidism
dihydroxyvitamin
methylene
treat secondary
treat
Prior art date
Application number
MX2015000076A
Other languages
English (en)
Spanish (es)
Inventor
Hector F Deluca
Margaret Clagett-Dame
Lori A Plum
Julia B Zella
Original Assignee
Wisconsin Alumni Reasearch Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015000076(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wisconsin Alumni Reasearch Foundation filed Critical Wisconsin Alumni Reasearch Foundation
Publication of MX2015000076A publication Critical patent/MX2015000076A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2015000076A 2012-06-29 2013-03-14 Uso de 2-metileno-19-nor- (20s) -1a, 25-dihidroxivitamina d3 para tratar el hiperparatiroidismo secundario. MX2015000076A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261666264P 2012-06-29 2012-06-29
PCT/US2013/031574 WO2014003849A1 (en) 2012-06-29 2013-03-14 USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D3 TO TREAT SECONDARY HYPERPARATHYROIDISM

Publications (1)

Publication Number Publication Date
MX2015000076A true MX2015000076A (es) 2015-04-10

Family

ID=47997980

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015000076A MX2015000076A (es) 2012-06-29 2013-03-14 Uso de 2-metileno-19-nor- (20s) -1a, 25-dihidroxivitamina d3 para tratar el hiperparatiroidismo secundario.

Country Status (19)

Country Link
US (4) US9205096B2 (cg-RX-API-DMAC10.html)
EP (1) EP2866811A1 (cg-RX-API-DMAC10.html)
JP (1) JP2015522015A (cg-RX-API-DMAC10.html)
KR (1) KR20150030673A (cg-RX-API-DMAC10.html)
CN (1) CN104394871A (cg-RX-API-DMAC10.html)
AU (1) AU2013281217B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014032847A2 (cg-RX-API-DMAC10.html)
CA (1) CA2877680C (cg-RX-API-DMAC10.html)
CL (1) CL2014003565A1 (cg-RX-API-DMAC10.html)
CO (1) CO7240358A2 (cg-RX-API-DMAC10.html)
HK (1) HK1206600A1 (cg-RX-API-DMAC10.html)
IL (1) IL236184A0 (cg-RX-API-DMAC10.html)
MX (1) MX2015000076A (cg-RX-API-DMAC10.html)
MY (1) MY172886A (cg-RX-API-DMAC10.html)
NZ (1) NZ703347A (cg-RX-API-DMAC10.html)
RU (1) RU2666995C2 (cg-RX-API-DMAC10.html)
SG (1) SG11201408731WA (cg-RX-API-DMAC10.html)
WO (1) WO2014003849A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201500119B (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY172886A (en) * 2012-06-29 2019-12-13 Wisconsin Alumni Res Found Use of 2-methylene-19-nor-(20s)-1?25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism
WO2015048573A1 (en) 2013-09-27 2015-04-02 Codexis, Inc. Structure based predictive modeling
DK3049973T3 (en) 2013-09-27 2018-10-22 Codexis Inc AUTOMATED SCREENING OF ENZYM VARIENTS
CN103533522A (zh) * 2013-10-25 2014-01-22 从兴技术有限公司 短信稽核的方法及系统
US10220047B2 (en) * 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
US9539264B2 (en) * 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
US10369161B2 (en) * 2014-12-30 2019-08-06 Wisconsin Alumni Research Foundation Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism
WO2018044468A1 (en) 2016-08-30 2018-03-08 Wisconsin Alumni Research Foundation COMBINATION OF LOW DOSE 2-METHYLENE-19-NOR-(20S)-1α, 25-DIHYDROXYVITAMIN D3 AND CALCIMIMETICS TO TREAT SECONDARY HYPERPARATHYROIDISM

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040043971A1 (en) 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US6306844B1 (en) 1997-03-17 2001-10-23 Wisconsin Alumni Research Foundation Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength
US5843928A (en) 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US6136799A (en) 1998-04-08 2000-10-24 Abbott Laboratories Cosolvent formulations
US6673782B2 (en) 1999-04-29 2004-01-06 Wisconsin Alumni Research Foundation Treatment of systemic lupus erythematosis
DK1267886T3 (da) 2000-03-27 2006-07-10 Wisconsin Alumni Res Found D-vitaminforbindelser anvendt til at stabilisere nyretransplantater
BR0112454A (pt) * 2000-07-14 2003-07-29 Wisconsin Alumni Res Found Métodos de tratamento de doença metabólica do osso, psorìase, leucemia, câncer do cólon, do seio ou da próstata e de aumento da força de um osso e uso de composto
US20080249068A1 (en) 2002-09-05 2008-10-09 Deluca Hector F Method of Extending the Dose Range of Vitamin D Compounds
US20050124591A1 (en) 2003-07-29 2005-06-09 Jin Tian Use of vitamin Ds to treat kidney disease
US20060171983A1 (en) 2003-07-30 2006-08-03 Jin Tian Use of Vitamin D receptor activators or Vitamin D analogs to treat cardiovascular disease
NZ545632A (en) * 2003-09-19 2009-09-25 Wisconsin Alumni Res Found 2-Alkylidene-19-nor-vitamin D derivatives for the treatment of frailty, muscle damage or sarcopenia
US7704980B2 (en) 2003-10-08 2010-04-27 Wisconsin Alumni Research Foundation Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
US7214671B2 (en) 2004-02-19 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
CA2597624C (en) 2005-02-11 2012-08-14 Wisconsin Alumni Research Foundation 2-methylene-19-nor-(20s-24s)-1.alpha.,25-dihydroxyvitamin-d2
US7528122B2 (en) * 2006-02-02 2009-05-05 Wisconsin Alumni Research Foundation Vitamin D analog—NEL, methods and uses thereof
JP5908402B2 (ja) * 2009-08-03 2016-04-26 ウィスコンシン・アルムニ・リサーチ・ファウンデーションＷｉｓｃｏｎｓｉｎ Ａｌｕｍｎｉ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 腎疾患の予防方法およびその症状を処置する方法
WO2011119610A2 (en) 2010-03-23 2011-09-29 Wisconsin Alumni Research Foundation (20S)-2-METHYLENE-19-NOR-22-DIMETHYL-1α,25- DIHYDROXYVITAMIN D3 AND (20R)-2-METHYLENE-19-NOR-22- DIMETHYL-1α,25-HYDROXYVITAMIN D3
MY172886A (en) * 2012-06-29 2019-12-13 Wisconsin Alumni Res Found Use of 2-methylene-19-nor-(20s)-1?25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism

Also Published As

Publication number Publication date
CO7240358A2 (es) 2015-04-17
SG11201408731WA (en) 2015-01-29
AU2013281217A1 (en) 2015-01-22
CA2877680C (en) 2017-08-29
US20160136184A1 (en) 2016-05-19
HK1206600A1 (en) 2016-01-15
RU2666995C2 (ru) 2018-09-13
AU2013281217B2 (en) 2017-03-02
MY172886A (en) 2019-12-13
ZA201500119B (en) 2017-11-29
EP2866811A1 (en) 2015-05-06
US9717744B2 (en) 2017-08-01
US20140187522A1 (en) 2014-07-03
CN104394871A (zh) 2015-03-04
US9034853B2 (en) 2015-05-19
US10046000B2 (en) 2018-08-14
BR112014032847A2 (pt) 2017-06-27
CA2877680A1 (en) 2014-01-03
WO2014003849A1 (en) 2014-01-03
KR20150030673A (ko) 2015-03-20
JP2015522015A (ja) 2015-08-03
US20140005152A1 (en) 2014-01-02
IL236184A0 (en) 2015-01-29
RU2015102831A (ru) 2016-08-20
US20170252360A1 (en) 2017-09-07
NZ703347A (en) 2016-05-27
CL2014003565A1 (es) 2015-08-28
US9205096B2 (en) 2015-12-08

Similar Documents

Publication Publication Date Title
MY172886A (en) Use of 2-methylene-19-nor-(20s)-1?25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism
CR20140376A (es) Compuestos para tratar la atrofia muscular espinal
PH12015500525A1 (en) Formulations of enzalutamide
SG11201404704UA (en) Database system using batch-oriented computation
UY34984A (es) Métodos para tratar o prevenir asma administrando un antagonista de il-4r.
PH12016502167A1 (en) Hdl theraphy markers
UA116196C2 (uk) Синтетичний міметик апеліну для лікування серцевої недостатності
IN2014CN04014A (cg-RX-API-DMAC10.html)
PH12016501965A1 (en) S1p modulator immediate release dosage regimen
BR112013008492A2 (pt) recipiente de revelador, dispositivo de revelação, cartucho de processo, dispositivo de formação de imagem, e método de reabastecimento de revelador
BR112013011259A2 (pt) condições de tratamento associadas com nível aumentado de eotaxina com 25-hidroxivitamina d3
GT201400223A (es) Sistemas y métodos para tratar una respuesta farmacodinámica adversa inducida por opioides
CL2017002304A1 (es) Métodos para tratar enfermedades
IN2015DN01524A (cg-RX-API-DMAC10.html)
AR089320A1 (es) Cepa de lactobacillus mucosae
MX354598B (es) Uso de neuregulina para tratar lesion de nervio periferico.
IN2015DN04070A (cg-RX-API-DMAC10.html)
CL2016001428A1 (es) Uso de una composicion con ejercicios cognitivos util para la prevencion o el tratamiento de un desarrollo cognitivo retrasado en los niños.
MX369774B (es) Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos.
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
BR112012024704A8 (pt) uso terapêutico de tetratiomolibdato.
IN2014KN01772A (cg-RX-API-DMAC10.html)
EP3240549A4 (en) Use of 2-methylene-19-nor-(20s)-1a,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism
ECSP17021138A (es) Compuestos de dipeptidil-cetoamida y su uso para el tratamiento y/o la prevención de la acumulación de grasa
MY164592A (en) Method for emulsion treatment